Navigation Links
Endo Pharmaceuticals Returns Product Rights to TRANSDUR(TM)-Sufentanil to DURECT
Date:2/27/2009

roved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit http://www.durect.com.

NOTE: POSIDUR(TM), SABER(TM), ORADUR(TM), TRANSDUR(TM), and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.

DURECT Forward-Looking Statement

The statements in this press release regarding TRANSDUR-Sufentanil, its potential attributes, its potential as an alternative to extended release opioid products, possible Phase III program, our intentions to enter into collaborations or further develop the program and anticipated regulatory pathway for this program are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the uncertainty and costs associated with the development and commercialization of certain opioid drug products such as TRANSDUR-Sufentanil due to increased scrutiny and possible new regulations relating to risk evaluation and mitigation of these drugs, our difficulty or failure to obtain approvals from regulatory agencies with respect to TRANSDUR- Sufentanil, design, enroll, conduct and complete clinical trials, complete the design, development, and manufacturing process development of TRANSDUR- Sufentanil, consummate collaborative agreements relating to TRANSDUR- Sufentanil, manufacture and commercialize and obtain marketplace acceptance of TRANSDUR-Sufentanil, avoid infringing patents held by other parties and secure and defend patents of our own, and manage and o
'/>"/>

SOURCE DURECT Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 22, 2015 Padre Murphy's and ... supporter of Pro Player Health Alliance (PPHA). The ... Murphy's in getting everyone, including NFL greats, treated for obstructive ... the leading groups supporting the cause in the valley. The ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, ... dresses. View website of AngelWeddingDress.com to find ... wedding dresses online for a bridal party. AngelWeddingDress offers ... for them. Its maternity wedding dresses are specially designed ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining the ... . , Auto insurance quotes help many drivers find ... necessary to call an agent or visit an agency for ... single website: http://autocarinsurancebest.com/ . , Every business who relies ...
(Date:1/22/2015)... 22, 2015 Yesterday, Senator Holly ... and Kristin Olsen (R-Modesto) were honored by the ... advancing biotechnology, biomedical science, medical device and pharmaceutical ... received the “2014 Life Sciences Champion” award from ...
(Date:1/22/2015)... 2015 EBSCO Information Services (EBSCO) ... their relationship in an effort to further promote visibility and ... EBSCO has long made AMA journals available via its subscription ... The JAMA Network. , Long known as both ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... , WEDNESDAY, May 30 (HealthDay News) -- Nearly one in four ... be triggered by hot summer weather. Hives are itchy, red ... can be acute or chronic, according to the American Academy of ... than a day or up to six weeks, are likely a ...
... Breast-cancer researchers at the University of Wisconsin-Madison have found that ... together as a team to maintain normal activity in mammary ... breast cell types. They may also drive the development and ... Journal of Biological Chemistry , the research also suggests ...
... , , , , , , ... AUDIO: Smoking researchers at Washington University School of Medicine in Sr. Louis have found that the same genetic variations that ... for more information. , , , , ... , , , , , , , ...
... that can rapidly screen cells for leukemia or HIV ... can produce three-dimensional focusing of a stream of cells, ... counting CD4 cells," said Tony Jun Huang, associate professor ... of the diagnoses are done using flow cytometry." ...
... in one side of their visual field benefit from ... hearing sounds for an hour, their visual detection of ... field improved significantly. Neural pathways that simultaneously process information ... have embarked on a whole new therapy approach" says ...
... TUESDAY, May 29 (HealthDay News) -- Women who develop fevers ... have a child with autism spectrum disorder or another developmental ... if, fevers may increase the risk for autism is unknown, ... if they do develop a fever while pregnant because taking ...
Cached Medicine News:Health News:Summer's Heat May Enflame Hives 2Health News:Breast stem-cell research: Receptor teamwork is required and a new pathway may be involved 2Health News:Breast stem-cell research: Receptor teamwork is required and a new pathway may be involved 3Health News:Genes predict if medication can help you quit smoking 2Health News:Genes predict if medication can help you quit smoking 3Health News:Genes predict if medication can help you quit smoking 4Health News:Biochip-based device for cell analysis 2Health News:Biochip-based device for cell analysis 3Health News:Hear to see: New method for the treatment of visual field defects 2Health News:Fever During Pregnancy May Raise Odds for Autism in Offspring 2Health News:Fever During Pregnancy May Raise Odds for Autism in Offspring 3
(Date:1/23/2015)... 2015 Gem Pharmaceuticals announced today that the initial ... the Company,s Phase 2 clinical trial.  This open-label study ... compound, GPX-150 (an investigational medication), in approximately 30 adults ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... Jan. 22, 2015  Uroplasty, Inc. (NASDAQ: UPI ), ... innovative proprietary products to treat voiding dysfunctions, today reported ... 31, 2014.  Global revenue for the Company,s ... million, a new quarterly revenue record, as compared to ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015  Profil Institute ... focused on diabetes and obesity, announced today a new ... Drug Development,  published by Springer, a leading global scientific ... extensively analyze and illustrate techniques for use in early ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3
... PARSIPPANY, N.J., July 7, 2011 Watson Pharmaceuticals, Inc. ... United States Court of Appeals for the Federal Circuit ... Southern District of Florida,s February 2011 decision that Watson,s ... Mucinex(R) DM (Dextromethorphan HBr/ Guaifenesin) Extended-Release products do not ...
... 2011 Watson Pharmaceuticals, Inc. (NYSE: ... Laboratories, Inc., filed an Abbreviated New Drug Application ... (FDA) seeking approval to market lisdexamfetamine dimesylate capsules. ... of Shire LLC,s Vyvanse®. Vyvanse® is a prescription ...
Cached Medicine Technology:Watson Confirms Favorable Appeals Court Decision in Mucinex(R) Patent Suit 2Watson Confirms Vyvanse® Patent Challenge 2
... 14A and 14C have been approved. The three ... the variations in the size of the individual ... are designed to stabilize the capsule and have ... of U.S. ophthalmologists. For implatations of the ...
... is a device designed for permanent implantation ... removal surgery. It provides secondary capsular bag ... The CTR is a uniplanar, 270-degree, semi-circle ... absorbing polymethylmethacrylate (PMMA) with one manipulation eyelet ...
Stainless steel cartilage scissors....
Hannum rongeur/grasper with teth in jaws and non-locking design....
Medicine Products: